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Abstract
West Nile virus (WNV) is a mosquito-borne flavivirus that infects the central nervous system of humans and other animals. In this study, we
found that C3H/HeN (C3H) mice exhibited a higher morbidity and mortality than C57BL/6 (B6) mice. We compared tissue tropism, viral
replication and kinetics for C3H and B6 mice during acute viral infection. WNV was detected in multiple tissues, including novel sites such as the
skin, duodenum and pancreas, but the tropism was identical for the two strains. Additionally, viral load and kinetics of spread did not differ
substantially between strains. Neuroinvasion occurred in both strains by day 3 post-inoculation with early detection in the olfactory bulbs and
spinal cord, suggesting that WNV neuroinvades at specific sites. Furthermore, neuroinvasion and viral load in the CNS did not predict disease
outcome. Our data suggest that the disparities in morbidity and mortality between C3H and B6 mice are not due to differences in tropism, viral
load or kinetics during acute WNV infection.
© 2007 Elsevier Inc. All rights reserved.Keywords: West Nile virus; Tissue tropism; Neuroinvasion; Disease susceptibilityIntroduction
West Nile virus (WNV) is a positive-sense, single-stranded
RNA flavivirus that is maintained in nature in an enzootic cycle
between mosquitoes and birds. Incidental infections of
mammals, including humans and horses, can occur. Humans
infected with WNV usually remain asymptomatic; however,
West Nile fever occurs in approximately 20% of infected
humans with symptoms such as fever, myalgia, and headache
(Petersen et al., 2002). In 1–2% of human WNV infections,
severe neurologic disease develops, including meningitis and
encephalitis, and permanent neurologic damage or death may
ensue with increased risk in the elderly (O'Leary et al., 2004;
Sejvar et al., 2003; Weiss et al., 2001). The case fatality rate is
approximately 12% for hospitalized encephalitic cases
(O'Leary et al., 2004). There were over 3800 cases of West
Nile (WN) disease, including over 110 deaths, in the United⁎ Corresponding author. Wadsworth Center, New York State Department of
Health, P.O. Box 509, Albany, NY 12201-0509, USA. Fax: +1 518 869 6487.
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doi:10.1016/j.virol.2007.06.033States during 2006 (CDC, 2006). Currently, there are no
treatments or vaccines approved for human use.
Rodent models have been used extensively to study WNV
infection (Eldadah and Nathanson, 1967; Lustig et al., 1992;
Weiner et al., 1970; Xiao et al., 2001). Clinical manifestations of
WN disease in the laboratory mouse closely resemble human
symptoms, providing a good model to studyWNV pathogenesis
(Kramer and Bernard, 2001). Previous work has shown that
mouse strains exhibit varying degrees of susceptibility to
flaviviruses (Darnell et al., 1974; Sangster et al., 1993). Wild
mice are resistant to infection, and resistance has been mapped
to the 2′,5′-oligoadenylate synthetase (OAS) gene, which plays
an important role in the Type I interferon pathway (Mashimo et
al., 2002; Perelygin et al., 2002). Laboratory mouse strains,
including the C3H/HeN (C3H) and C57BL/6 (B6), are sus-
ceptible to infection because of a truncation in the OAS gene,
which is functional in wild mice. The flavivirus-resistant allele
has been introduced in laboratory strains by backcrossing with
wild mice and selecting for the resistant phenotype, producing a
resistant laboratory strain, C3H/RV (Darnell et al., 1974). In
vivo studies using C3H/RV-resistant and C3H susceptible
Fig. 1. Survival analysis of C3H and B6 mice after WNV infection. Six-
week-old female B6 (n=94) and C3H mice (n=68) were inoculated
subcutaneously in the left rear footpad with 103 PFU of WNV. All mice were
observed for 28–35 days p.i. Data are combined from multiple independent
studies. Mortality was statistically different by Chi-squared analysis (Pb0.001).
Viral infection was confirmed in all survivors by seroconversion to WNV.
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replication and kinetics in peripheral and central nervous
system tissues (Brinton, 1986).
Although all laboratory mice naturally lack the flavivirus
resistance gene and are susceptible to WNV infection, different
strains display varying degrees of disease. In this study, we
compared two mouse strains, C3H and B6, which exhibited
different morbidity and mortality rates. Based on previous
work comparing resistant and susceptible mouse strains
(Brinton, 1986; Darnell et al., 1974; Mashimo et al., 2002;
Perelygin et al., 2002; Sangster et al., 1993), we predicted that
tissue tropism, viral burden, and/or kinetics of spread would
differ between C3H and B6 mice. Our findings did not support
this prediction, however, suggesting that tissue tropism and
viral replication of WNV during acute infection are not
responsible for the disparity in survival rate between strains.
Additionally, we detected WNV in the central nervous system
of all C3H and B6 mice 3 to 7 days after infection, including
mice that would remain without clinical disease, indicating that
neuroinvasion does not necessarily lead to morbidity and
mortality. Finally, WNV was detected in all tissues tested
except for the liver, and skin, Peyer's patch, duodenum,
pancreas, and lung were identified as novel sites of WNV
replication.
Results
C3H mice are more susceptible to WN disease than are B6
mice
We compared the morbidity and mortality rates of C3H and
B6 mice to determine the effect of mouse strain on WN disease.
Following a subcutaneous inoculation with 103 PFU, C3H mice
exhibited 92% morbidity and 58% mortality, whereas the B6
mice exhibited 33% morbidity and 25% mortality (Table 1).
Disease onset occurred in both strains between days 7 and 9
post-inoculation (p.i.) with average survival times of 10.1 days
for C3H mice and 9.3 days for B6 mice (Table 1), and there was
no difference in ID50 for the two strains (data not shown). On
repeated studies, C3H and B6 mice exhibited survival rates of
22% and 78%, respectively (Fig. 1); these results are statis-
tically significant (Pb0.001 Chi-squared test). These data
clearly show that the C3H mice are more susceptible to WN
disease compared to B6 mice.Table 1
C3H mice are more susceptible to WN disease than are B6 mice
Mouse
strain
Disease onset
(days p.i.)
Morbidity
(# sick/total)
Mortality
(# died/total)
ASTa (SD)
C57BL/6 (B6) 7–9 4/12 b 3/12 9.3 days (1.1)
C3H/HeN (C3H) 7–9 11/12b 7/12 10.1 days (3.1)
Six-week-old B6 and C3H female mice were inoculated subcutaneously in the
left-rear footpad with 103 PFU of WNVand were monitored for weight loss and
clinical signs daily.
a AST=average survival time calculated for mice that died only. SD=
standard deviation.
b Results are statistically different (P=0.003, Chi-squared test).Viral burden and replication kinetics do not differ substantially
between C3H and B6 mouse strains at the inoculation site or in
peripheral tissues
WNV burden was compared between the two strains at the
initial sites of replication and in peripheral tissues to establish
whether the lower C3H survival rate correlated with a difference
in tissue tropism or higher viral load. C3H and B6 mice were
inoculated subcutaneously with 103 PFU, and viral burden was
assessed in serum, ipsilateral footpad, contralateral footpad,
ipsilateral draining lymph node, contralateral draining lymph
node, and spleen at 12 h and 1, 2, 3, 4, 5, 6, and 7 days p.i.
Viremia
C3H mice had a higher viremia (geometric mean 102.1 PFU/
ml) at 1 day p.i. compared to B6 mice (geometric mean 101.7
PFU/ml) (Fig. 2A), but the difference is not statistically
significant. Viremia titers were nearly equivalent on day 2 p.i
(∼104 PFU/ml) and peaked in both strains on day 3 p.i. (∼104
PFU/ml).Onday5p.i., five of the sevenC3Hmice haddetectable
virus in serum, whereas all B6 mice had cleared the virus,
resulting in a significant difference in viral burden between the
two strains (P=0.02). All mice had cleared the virus by day 7 p.i.
Ipsilateral footpad (inoculation site)
WNV burden at the footpad inoculation site was below
the limit of detection (LOD) for all mice 12 h p.i. (Fig. 2C).
At 1 day p.i., C3H mice had a significantly higher viral
load than did B6 mice (geometric means of 104.6 PFU/g
versus 103.2 PFU/g; P=0.004). There was no significant
difference in viral replication between mouse strains on days
2 through 7 p.i.; however, the C3H mice had slightly higher
titers at each time point. WNV load remained high in all mice
7 days p.i. (C3H geometric mean=106.2 PFU/g, B6 geometric
mean=105.4 PFU/g).
Contralateral footpad
We observed a higher viral burden at the site of inoculation
over time, suggesting that WNV is able to replicate in skin
tissue. Infectious virus was assayed in the footpad contralateral
Fig. 2. Viral burden and replication kinetics in inoculation site and other peripheral tissues of C3H and B6 mice. Six-week-old female C3H and B6 mice were inoculated subcutaneously with 103 PFU of WNV in the left
rear footpad, and tissues were harvested at various times post-inoculation. Viral load was measured in serum (A), spleen (B), ipsilateral footpad (C), contralateral footpad (D), ipsilateral popliteal lymph node (E), and
contralateral popliteal lymph node (F) by plaque assay on Vero cells and is reported as PFU per gram of tissue or PFU per milliliter of serum. Each data point represents an individual mouse, and data from 3
independent experiments are shown. The dotted line corresponds to the limit of detection (LOD). The LOD is 102.7 PFU/g and 101.7 PFU/ml for tissues and sera, respectively. Data points below the dotted line are
less than the LOD. The solid horizontal lines signify the geometric means of three mice per group at 12 h and 3, 4 and 6 days p.i., seven mice per group at days 1, 2, and 5 p.i., and four C3H mice and three B6
mice at 7 days p.i. Values of 333 PFU/g for tissues and 33 PFU/ml for serum were used to calculate the geometric means and standard deviations for any samples below the LOD. Statistical differences between
C3H and B6 mice are noted with ** (Pb0.01) or *** (Pb0.001).
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Table 2
WNV burden in peripheral tissues of C3H and B6 mice
Tissue C3H C57BL/6
Titer
range a
(log10 PFU/g)
Days
positive
(p.i.)
# Mice
with
positive
tissue/
total b
Titer
rangea
(log10
PFU/g)
Days
positive
(p.i.)
# Mice
with
positive
tissue/
totalb
Liver bLOD NA 0/25 c bLOD NA 0/24c
Heart 2.7–5.1 3–7 13/16 2.7–5.3 3–7 12/15
Lung 2.7–5.6 2–7 16/19 2.7–5.7 2–7 10/18
Kidney 3.0–6.0 3–7 13/16 2.7–5.7 2–7 16/18
Duodenum 2.7–5.8 3–7 14/20 2.7–5.5 5–7 7/13
Pancreas 2.7–5.5 4–7 10/13 2.7–5.2 4–6 5/9
Peyer's
patch
2.7–6.3 2–7 12/19 2.7–5.5 3–7 12/15
Thymus 2.7–5.8 2–7 20/24 3.5–6.3 2–7 19/23
Six-week-old female C3H and B6 mice were inoculated subcutaneously in the
left rear footpad with 103 PFU of WNV. Mice were sacrificed, perfused with
buffer, and tissues were harvested at 12 h and days 1, 2, 3, 4, 5, 6, and 7 post-
inoculation (p.i.). These data represent three independent experiments as
described in Materials and methods. Viral burden was not statistically
significant between the two strains at any time point.
a Limit of detection (LOD) for all peripheral tissues is 102.7 PFU/g.
b Total tested equals number of mice sacrificed on days on which at least one
mouse was positive.
c All liver samples were negative for virus from 12 h to 7 days p.i.
425A.N. Brown et al. / Virology 368 (2007) 422–430to the inoculation site, to determine whether skin, other than at
the inoculation site, supports viral replication. Virus was
undetectable in all C3H and B6 mice sacrificed at 12 h and at
1 day p.i. (Fig. 2D). A significant difference in the number of
mice with WNV-positive tissue was observed on day 2; three of
the seven C3H mice were positive for WNV, but all of the B6
mice remained below the LOD (P=0.05 Chi-squared test). Viral
replication was observed in both strains on day 3 p.i. and
continued through day 7 p.i., by which point all mice had a
considerable viral load (∼105 PFU/g). There was substantial
variability in WNV burden from mouse to mouse, and no
significant difference between strains was found at any time
point.
Draining lymph node
Virus was present in the draining popliteal lymph node
beginning at 12 h p.i. in both strains (Fig. 2E). It is possible that
virus detected at 12 h p.i. was from the input inoculum, but by
1 day p.i., the viral titers were higher, suggesting viral
replication. On day 2 p.i., B6 mice had a significantly higher
viral burden than did C3H mice (P=0.0006); however, viral
titers in C3H mice continued to increase through day 4 p.i. and
were significantly higher than titers in B6 mice by day 5 p.i.
(P=0.02). On day 7 p.i., equivalent geometric mean titers of 104
PFU/g were found in the draining lymph nodes of both C3H and
B6 mice.
Spleen and contralateral lymph node
Infectious virus was assayed in the spleen and contralateral
lymph node to determine WNV spread and replication in other
lymphoid tissues. Infectious virus was detected on day 1 p.i. in
five of the 14 mice (4 C3H, 1 B6) (Fig. 2B). By day 2 p.i.,
spleens of all mice were positive with significantly higher titers
in the C3H mice (P=0.0006). Viral burden peaked in both
mouse strains on day 4 p.i., yielding geometric means of 105.3
PFU/g in C3H mice and 106 PFU/g in B6 mice. By day 7 p.i.,
virus persisted in the spleens of both mouse strains, for six of the
seven mice.
In contrast to the spleen, WNV was not detected in the
contralateral popliteal lymph node until day 2 p.i. and was at
equivalent levels (∼103 PFU/g) in the two mouse strains (Fig.
2F). Viral burden remained fairly constant between days 3 and 5
p.i (between 104 and 105 PFU/g) and decreased on day 6 p.i. By
day 7 p.i., viral levels approached the LOD in B6 mice, but were
approximately 10-fold higher in C3H mice; nevertheless, these
results were not statistically significant (PN0.05). These results
suggest that WNV spreads to spleen and other lymph nodes
similarly in both C3H and B6 strains.
Tissue tropism is the same for C3H and B6 mouse strains
We determined whether the higher C3H mortality could be
due to differences in tropism and/or viral replication and spread,
by comparing viral loads over time in other peripheral tissues of
C3H and B6 mice. WNV was pantropic in both mouse strains,
infecting all tissues except the liver (Table 2). Throughout the
course of infection, no infectious virus was isolated from anyliver sample, suggesting an inability of the virus to replicate in
this tissue. In contrast, virus was detected in every other
harvested tissue including the heart, lung, kidney, duodenum,
pancreas, Peyer's patch, and thymus. Viral burden in these
tissues were similar between strains, ranging from the LOD
(102.7 PFU/g) to as high as 106.3 PFU/g. C3H mice had higher
viral loads in the thymus early in infection (between 2 and
4 days p.i.) than did B6 mice; however, later in infection (days 5
through 7 p.i.) viral titers were at least 10-fold higher in the B6
mice when compared to C3H mice (data not shown). The
Peyer's patches illustrated a similar trend in which the B6 mice
had nearly 100 times the viral burden of the C3H mice on days 6
and 7 p.i. (C3H geometric mean=104.3 and B6 geometric
mean=106.0; data not shown). In addition, variable amounts of
WNV were detected in skeletal muscle of C3H mice (data not
shown); this tissue was not tested in B6 mice.
WNV spread with similar kinetics to peripheral tissues in the
two mouse strains. Infectious virus was first detected in the
heart, lung, kidney, Peyer's patch, and thymus of both C3H and
B6 mice 2 to 3 days p.i., and persisted through day 7 p.i. Slight
differences were observed for some of the tissues. Pancreatic
samples had detectable virus beginning 4 days p.i. in both
strains; by day 7 p.i. 75% of the C3H mice (three of four) were
still positive for infection, but virus was completely cleared
from the B6 mice. In the duodenum, virus was detected 2 days
earlier in the C3H mice than in B6 mice (3 days p.i. versus
5 days p.i.), but virus persisted in both strains through day 7 p.i.
The numbers of mice with WNV-positive tissues did not
differ substantially between the two strains. Similar percentages
of C3H and B6 mice were positive for viral infection in heart
(81% versus 80%), kidney (81% versus 89%), and thymus
Fig. 3. Viral burden and replication kinetics in the central nervous system of C3H andB6mice. Six-week-old female C3H andB6micewere inoculated subcutaneously with 103 PFU ofWNVin the left rear footpad, and the
spinal cord and regions of the brain were harvested at various times p.i. Levels of infectious virus were measured by plaque assay on Vero cells and are reported as PFU per gram of tissue in the olfactory bulbs (A), cerebral
cortex (B), cerebellum (C), brainstem (D), the average for the four brain regions (E), and spinal cord (F). Each data point represents an individual mouse, and data from 2 independent experiments (A–D) or 3 independent
experiments (E and F) are shown. The solid horizontal lines signify the geometric means for each group. The dotted line corresponds to the limit of detection (LOD). Data points below the dotted line are less than the LOD.
The LODs as PFU per gram of tissue are: 102.4 for individual brain regions (A–D), 101.8 for average brain (E), and 102.1 for spinal cord (F). Values of 167 PFU/g for brain regions, 42 PFU/g for average brain, and 83 PFU/g
for spinal cord were used to calculate the geometric means for any samples below the LOD.
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427A.N. Brown et al. / Virology 368 (2007) 422–430(83% versus 83%). For the lung, duodenum, and pancreas, more
C3H mice than B6 mice were positive. The opposite was the
case for the Peyer's patch; this tissue was positive in only 61%
of the C3H mice, and 80% of B6 mice. However, these
comparisons do not attain statistical significance.
Neuroinvasion occurs in all mice by day 3 p.i., and viral
burden does not differ between C3H and B6 mouse strains in
the central nervous system
We determined whether viral load in the central nervous
system correlated with greater mortality of the C3H mouse
strain. Infectious virus was detected in the central nervous
system of all mice, regardless of strain, by day 3 p.i. (Fig. 3). At
this time point, viral burden was particularly high in the
olfactory bulbs (C3H geometric mean=104.1 PFU/g, B6
geometric mean=103.3 PFU/g) whereas the cerebral cortex,
cerebellum, and brainstem had viral loads ranging from below
the LOD (102.4 PFU/g) to 102.7 PFU/g in both mouse strains
(Fig. 3). WNV was detected in the spinal cords of all mice
3 days p.i. (Fig. 3); there was no statistical difference between
WNV titers in the spinal cord and in the olfactory bulbs. These
data suggest that neuroinvasion occurs simultaneously at
spatially distant sites (e.g., spinal cord and olfactory bulb) via
neuronal and/or hematogenous routes. Furthermore, WNV was
detected with similar frequency in the cranial and/or caudal
portions of the spinal cord on day 3 (data not shown),
supporting the idea of multiple entry sites into the central
nervous system instead of ascending or descending spread.
WNV burden and kinetics in the brains of C3H and B6 mice
were nearly identical throughout the course of infection.
Olfactory bulb titers remained fairly constant in both strains
on days 4 and 5 p.i. (between 104 to 105 PFU/g), and sub-
sequently increased on days 6 and 7 p.i. (∼106 PFU/g) (Fig. 3A).
Viral burden was variable in the other brain regions, although
remaining fairly low (between 103 and 104 PFU/g) on days 4
to 6 p.i. (Figs. 3B, C and D). An increase in viral load was
observed on day 7 p.i. in the cerebral cortex and brainstem
for both C3H and B6 mice. Cerebellum titers were variable
7 days p.i. with a trend toward higher viral burden in the C3H
mice (geometric mean of 104.3 PFU/g for C3H and 102.5
PFU/g for B6). Average WNV loads in the brains and spinal
cords of C3H and B6 mice were not significantly different
(Figs. 3E and F). Brain titers were fairly constant between days
3 and 5 p.i. and subsequently increased on days 6 and 7 p.i. Viral
levels peaked in the spinal cord for both mouse strains on day
4 p.i. (∼104 PFU/g) and decreased approximately 10-fold by
day 5 p.i. The viral titers in the spinal cord were more
variable on day 7 p.i., especially in the C3H mice.
Infectious virus in the brain was greater than virus in the
spinal cord during the later stages of infection. On day 6 p.i.,
viral loads in the brains of C3H and B6 mice (geometric means
of 105.1 PFU/g and 105.6 PFU/g, respectively) were at least 100-
fold higher than spinal cord titers (C3H geometric mean=103.2
PFU/g, B6 geometric mean=102.8 PFU/g). Similar results were
observed on day 7 p.i. Brain titers were significantly greater than
spinal cord titers by over 100-fold in the C3H mice (P=0.015)and by 400-fold in B6 mice (P=0.001). These data suggest that
virus preferentially replicates in brain tissue compared to spinal
cord tissue, during the later stages of infection.
Discussion
In this study we have shown that adult C3H mice are more
susceptible to WN disease with a greater morbidity and
mortality than are adult B6 mice. The lower C3H survival did
not correlate with higher viremia, differences in tissue tropism,
higher viral load in peripheral tissues, earlier entry in the central
nervous system, or higher viral burden in the brain and spinal
cord. Viral burden and kinetics were nearly identical in the two
strains through day 7 p.i. Thus, these two mouse strains will be
useful for the identification of disease correlates other than viral
tropism and replication.
In these experiments we have found that WNV is pantropic,
with virus detectable in all tissues assayed, except the liver. We
observed substantial viral burden in serum, ipsilateral and
contralateral footpads, ipsilateral and contralateral lymph nodes,
spleen, heart, lung, kidney, skeletal muscle, duodenum,
pancreas, Peyer's patches, and thymus. These data are
consistent with findings of previous studies, which report
WNV dissemination to peripheral tissues (Diamond et al., 2003;
Kramer and Bernard, 2001; Shrestha et al., 2006; Wang et al.,
2003; Weiner et al., 1970), but ours is the first study to report
infectious WNV in skin, Peyer's patches, duodenum, pancreas,
and lung of wild-type mice. Many of the permissive tissues are
lymphoid organs (lymph node, spleen, thymus and Peyer's
patch), but other tissue types are also permissive. The
pantropism of WNV suggests that a cell type common to the
various tissues is an important cell target, e.g., a dendritic or
endothelial cell. On the other hand, WNV does not replicate in
the liver, despite the presence of common cell types. It is unclear
why the liver is not permissive for WNV in mice, especially
given that WNV is detected in the livers of birds (Panella et al.,
2001; Steele et al., 2000).
Our studies suggest that skin supports viral replication. In
one report, WNV RNAwas isolated from wild-type mouse skin
samples at the inoculation site 1 and 3 days p.i. (Schneider et al.,
2006). These results are consistent with our finding of infectious
virus in the ipsilateral footpad 1 day p.i.; however, we also
showed that viral load increased with time and that virus spread
to distant areas of skin, including the footpad contralateral to the
site of inoculation. Finally, a substantial viral burden persisted
through day 7 in both skin sites. The initial target cell for WNV
following a subcutaneous inoculation is currently unknown.
Our data suggest that skin cells are permissive for viral
replication and thus may be an initial target. Additionally, we
saw replication early in the draining lymph node. Virus detected
at 12 h p.i. may represent input virus draining to the lymph
node. By day 1 p.i., the viral load is increasing, likely indicative
of replication. These data together indicate two initial cell
targets, one in the skin and one in the draining lymph node.
We are also the first to show WNV burden in the duodenum
and pancreas of wild-type mice. A recent report has shown that
a mouse-adapted dengue virus strain can replicate in the small
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α/β and IFN-γ (Shresta et al., 2006). Enteritis and pancreatitis
were observed in birds infected with WNV (Steele et al., 2000).
In humans, pancreatitis was described in earlier outbreaks of
WNV (Petersen and Marfin, 2002). In addition, gastrointestinal
complaints, including diarrhea, are fairly common symptoms in
human patients with WN disease (Asnis et al., 2000; Chowers et
al., 2001; Weiss et al., 2001). Thus, our data suggest that WNV
may cause direct damage and pathology in the intestines and
pancreas, which may explain clinical manifestations in human
patients.
In our study, the olfactory bulbs and spinal cord were the first
regions of the central nervous system positive for infectious
WNV; all mice were positive in both regions on day 3 p.i. These
results suggest that neuroinvasion occurs preferentially at these
sites, possibly via peripheral nerves, rather than randomly via
infection of endothelial cells or a compromised blood brain
barrier. On the other hand, the olfactory bulbs and spinal cord
may be more permissive for viral replication, which would also
explain earlier detection in these regions. Furthermore, our
studies showed that after day 2 p.i., all mice exhibited a
disseminated infection in the central nervous system. This is
particularly remarkable given that approximately 70% of B6
mice do not exhibit any clinical disease after WNV infection (as
determined by morbidity and mortality studies). Furthermore,
all B6 mice had a substantial viral burden in the brain and spinal
cord, especially on day 7 p.i. These data suggest that
neuroinvasion and replication in the CNS do not necessarily
result in neurologic disease. Thus, it is possible that humans
with West Nile fever may have unrecognized infections of the
CNS, which may explain the recent reports of neurologic
sequelae in patients with West Nile fever (Carson et al., 2006;
Watson et al., 2004).
Some of our results on tissue tropism and kinetics of spread
contrast with the reports of other investigators using wild-type
mice (Diamond et al., 2003; Hunsperger and Roehrig, 2006;
Samuel et al., 2006; Samuel and Diamond, 2005; Wang et al.,
2003). In particular, we observed neuroinvasion by 3 days p.i.,
and others found that neuroinvasion first occurs in wild-type
mice from 1 to 7 days p.i (Beasley et al., 2005; Davis et al.,
2004; Diamond et al., 2003; Hunsperger and Roehrig, 2006;
Monath et al., 1983; Shrestha et al., 2006; Y. Wang et al., 2003;
T. Wang et al., 2004). These discrepancies may be attributed to
differences in viral strain, dose, and route of inoculation.
Additionally, assay sensitivity may play a role in the ability to
detect virus. For example, Hunsperger and Roehrig (2006)
detected WNV RNA in the brain as early as day 1 p.i., using
quantitative reverse transcriptase (RT)-PCR, which is more
sensitive than plaque assays. In addition, several investigators
perform plaque assays using BHK cells, which are 100-fold less
susceptible to WNV than Vero cells (Scholle et al., 2004).
We have shown that C3H mice are more susceptible to WN
disease, and B6 mice are more resistant. Previous studies
comparing WNV infection between resistant and susceptible
laboratory mouse strains found alterations in tissue tropism,
viral load, and kinetics of spread (Brinton, 1986). Comparable
differences were also observed in studies involving immuno-competent and immunodeficient mouse strains (Diamond et al.,
2003; Samuel et al., 2006; Samuel and Diamond, 2005;
Shrestha et al., 2006). In contrast, we saw identical tropism
and kinetics of spread between C3H and B6 mice inoculated
subcutaneously with WNV. Viral load was very similar between
the two strains; however, significant differences were observed
in the serum, ipsilateral footpad, draining lymph node, and
spleen. These differences were only observed at a single time
point and did not persist throughout the course of infection.
Thus, most likely these slightly elevated viral levels early in
infection are not responsible for the higher C3H morbidity and
mortality rates. On the other hand, viremia in the C3H mice was
1 day longer than in the B6 mice, suggesting a delay in viral
clearance in the C3H mice. Thus, the disparity in survival rate
may be attributed to differences in innate and adaptive immune
responses, affecting viral clearance. Virus persisted in the
tissues of both mouse strains 7 days p.i., indicating that
clearance had not yet occurred from the CNS or peripheral
tissues. Future studies will examine the kinetics of WNV
clearance and will use the C3H and B6 mice to identify
correlates of West Nile disease.
Materials and methods
Viruses and cells
WNV was produced from a full-length cDNA clone of a
2000 New York strain by electroporation of BHK-21 cells with
in vitro transcribed RNA as previously described (Shi et al.,
2002). Viral stock titers were determined by plaque assay on
African green monkey kidney cells (Vero, ATCC #CCL-81) as
previously described (Reisen et al., 1993). Vero cells were
maintained in MEM media [minimal essential medium (MEM,
Gibco® Invitrogen, Carlsbad, CA) supplemented with 10%
FBS, 2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 100 U/ml
of penicillin, and 100 μg/ml of streptomycin] and incubated at
5% CO2, 37 °C.
Mice
Five-week-old, female C3H/HeN and C57BL/6 mice were
purchased from Taconic (Germantown, NY), acclimatized for at
least 1 week in the biosafety-level-3 animal facility, and given
food and water ad libitum. All studies were approved by the
Institutional Animal Care and Use Committee of the Wadsworth
Center and followed criteria established by the National
Institutes of Health.
Morbidity and mortality study in mice
Six-week-old C3H and B6 mice were inoculated sub-
cutaneously in the left rear footpad with 10 μl inoculum,
using a 30-gauge needle and 100 μl glass syringe (Hamilton,
Reno, NV). The rear footpad was used in order to follow viral
spread to the draining lymph node in subsequent tissue
tropism studies. Four mice from each strain were inoculated
with diluent alone, and 12 mice per strain were inoculated
429A.N. Brown et al. / Virology 368 (2007) 422–430with WNV at 103 PFU. On repeated studies, 8–12 mice per
strain were virus-inoculated. The diluent for viral inocula was
endotoxin-free PBS (tissue culture grade; Invitrogen) with 1%
FBS. All mice were observed for clinical disease at least
once per day for the entire study, and all mice were weighed
daily for at least 14 days post-inoculation (p.i.) and three
times weekly for the duration of the study. Clinical signs
included ruffled fur, ataxia, weakness, and weight loss.
Morbidity was defined as clinical signs for at least 2 days
and/or greater than 9% weight loss. Mice that exhibited severe
disease were euthanized. No clinical signs or weight loss were
observed in mock-inoculated mice. All surviving mice were
bled at 28–35 days post-inoculation, and viral infection was
confirmed in all WNV-inoculated survivors, by seropositivity
on an ELISA for WNV-specific antibodies, as described
previously (Ebel et al., 2002).
Tissue harvest and viral quantification in mice
Six-week-old C3H and B6 mice were inoculated as
described above for all virus quantification studies. Three
mice from each strain were inoculated with diluent alone, and
24 to 25 mice per strain were inoculated with 10 μl containing
103 PFU of virus. Three to four virally infected mice per strain
were euthanized per time point, at 12 h and at 1, 2, 3, 4, 5, 6, and
7 days p.i. Tissues harvested at each time point included: serum,
ipsilateral (left) rear footpad (inoculation site), ipsilateral (left)
popliteal lymph node (draining lymph node), contralateral
(right) rear footpad, contralateral (right) popliteal lymph node,
spleen, thymus, heart, lung, duodenum, kidney, caudal and
cranial spinal cord, and regions of the brain (olfactory bulbs,
cerebral cortex and forebrain, cerebellum, and brainstem). Prior
to tissue harvest, all mice were perfused with PBS with 1% FBS
at 6 ml/min for approximately 15 min. Studies on C3H and B6
were performed in two independent experiments, not concur-
rently. In a third experiment, C3H and B6 mice were inoculated
simultaneously, and selected tissues were harvested after
sacrifice on days 1, 2, and 5 p.i. These tissues included:
serum, ipsilateral (left) rear footpad (inoculation site), ipsilateral
(left) popliteal lymph node (draining lymph node), contralateral
(right) rear footpad, contralateral right popliteal lymph node,
spleen, thymus, duodenum, right half of the brain, and the entire
spinal cord. In all studies, tissues were removed, placed in a
microfuge tube with a 4.5 mm BB, and weighed. BA-1 diluent
(M199, 1% bovine serum albumin, 0.05 M Tris pH 7.6, 0.35 g/l
sodium bicarbonate, 100 μg/ml penicillin, 100 μg/ml strepto-
mycin, 1 μg/ml fungizone) was added to make a 20%
homogenate for all central nervous system tissues, and a 10%
homogenate for all other tissues. Samples were frozen at
−80 °C for later titration.
Samples were processed on the day of viral titration. Tissues
were homogenized using a mixer mill (Qiagen, Valencia, CA) at
24 cycles per second for 4 min, centrifuged at 5800×g for 4 min,
and placed on ice. Viral burden of the homogenates were
assessed by plaque assay on Vero cells as previously described
(Reisen et al., 1993). The LODs were 50 PFU/ml for serum, 250
PFU/g for central nervous system tissue, and 500 PFU/g for allother tissues. When averages were calculated from multiple
regions of the brain and spinal cord, LODs were 62 PFU/g for
brain, and 125 PFU/g for spinal cord.
Statistical analysis
A P value of b0.05 was used as a cutoff for statistical
significance. For morbidity and mortality experiments, sig-
nificant differences were determined using a Microsoft Excel
Chi-squared test. For viral titration experiments, the Mann–
Whitney test (GraphPad, San Diego, CA) was used to assess the
difference in viral burden between the two mouse strains. For
samples with a viral load below the LOD, geometric means and
standard deviations were calculated using the next level of assay
sensitivity instead of a value of zero.
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